$62.41
+1.45
(+2.38%)▲
2.77%
Downside
Day's Volatility :3.99%
Upside
1.26%
10.19%
Downside
52 Weeks Volatility :44.38%
Upside
38.07%
Period | Exact Sciences Corporation | |
---|---|---|
3 Months | -7.65% | |
6 Months | -2.55% | |
1 Year | -5.74% | |
3 Years | -53.41% |
Market Capitalization | 11.3B |
Book Value | $17.34 |
Earnings Per Share (EPS) | -1.13 |
PEG Ratio | -1.07 |
Wall Street Target Price | 90.66 |
Profit Margin | -8.17% |
Operating Margin TTM | -11.94% |
Return On Assets TTM | -3.04% |
Return On Equity TTM | -6.6% |
Revenue TTM | 2.5B |
Revenue Per Share TTM | 13.88 |
Quarterly Revenue Growth YOY | 17.0% |
Gross Profit TTM | 1.5B |
EBITDA | -102.2M |
Diluted Eps TTM | -1.13 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.85 |
EPS Estimate Next Year | 0.06 |
EPS Estimate Current Quarter | -0.46 |
EPS Estimate Next Quarter | -0.38 |
What analysts predicted
Upside of 45.27%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 454.5M | ↑ 70.86% |
Net Income | -175.1M | ↑ 53.11% |
Net Profit Margin | -38.54% | ↑ 4.47% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 876.3M | ↑ 92.82% |
Net Income | -84.0M | ↓ 52.04% |
Net Profit Margin | -9.59% | ↑ 28.95% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.5B | ↑ 70.19% |
Net Income | -848.5M | ↑ 910.24% |
Net Profit Margin | -56.9% | ↓ 47.31% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.8B | ↑ 18.49% |
Net Income | -595.6M | ↓ 29.81% |
Net Profit Margin | -33.71% | ↑ 23.19% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 2.1B | ↑ 17.95% |
Net Income | -623.5M | ↑ 4.68% |
Net Profit Margin | -29.91% | ↑ 3.8% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.5B | ↑ 19.93% |
Net Income | -204.1M | ↓ 67.26% |
Net Profit Margin | -8.17% | ↑ 21.74% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 523.1M | ↑ 0.27% |
Net Income | -148.8M | ↓ 10.42% |
Net Profit Margin | -28.44% | ↑ 3.39% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 553.0M | ↑ 5.72% |
Net Income | -127.7M | ↓ 14.13% |
Net Profit Margin | -23.1% | ↑ 5.34% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 602.5M | ↑ 8.94% |
Net Income | -74.2M | ↓ 41.95% |
Net Profit Margin | -12.31% | ↑ 10.79% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 622.1M | ↑ 3.26% |
Net Income | -81.0M | ↑ 9.27% |
Net Profit Margin | -13.02% | ↓ 0.71% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 628.3M | ↑ 1.0% |
Net Income | 794.0K | ↓ 100.98% |
Net Profit Margin | 0.13% | ↑ 13.15% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 646.9M | ↑ 2.95% |
Net Income | -49.8M | ↓ 6367.76% |
Net Profit Margin | -7.69% | ↓ 7.82% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.5B | ↑ 154.61% |
Total Liabilities | 843.1M | ↑ 978.91% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 3.5B | ↑ 130.03% |
Total Liabilities | 1.2B | ↑ 44.44% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 4.9B | ↑ 40.49% |
Total Liabilities | 2.1B | ↑ 72.59% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 6.7B | ↑ 35.73% |
Total Liabilities | 3.3B | ↑ 56.89% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 6.2B | ↓ 6.85% |
Total Liabilities | 3.2B | ↓ 3.44% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 6.5B | ↑ 3.93% |
Total Liabilities | 3.3B | ↑ 4.47% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 6.3B | ↓ 2.03% |
Total Liabilities | 3.2B | ↓ 0.93% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 6.2B | ↓ 1.26% |
Total Liabilities | 3.2B | ↓ 0.44% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.3B | ↑ 1.24% |
Total Liabilities | 3.2B | ↑ 1.98% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.4B | ↑ 0.81% |
Total Liabilities | 3.3B | ↑ 1.61% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.4B | ↑ 1.03% |
Total Liabilities | 3.3B | ↑ 0.02% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.5B | ↑ 0.79% |
Total Liabilities | 3.3B | ↑ 0.8% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -69.3M | ↓ 3.34% |
Investing Cash Flow | -781.9M | ↑ 386.25% |
Financing Cash Flow | 934.1M | ↑ 257.97% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -115.0M | ↑ 65.9% |
Investing Cash Flow | -121.1M | ↓ 84.52% |
Financing Cash Flow | 253.2M | ↓ 72.9% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 136.5M | ↓ 218.67% |
Investing Cash Flow | -702.0M | ↑ 479.85% |
Financing Cash Flow | 1.9B | ↑ 642.4% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -102.2M | ↓ 174.91% |
Investing Cash Flow | -1.1B | ↑ 54.14% |
Financing Cash Flow | 8.5M | ↓ 99.55% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -223.6M | ↑ 118.67% |
Investing Cash Flow | 74.1M | ↓ 106.84% |
Financing Cash Flow | 76.5M | ↑ 802.8% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -40.9M | ↓ 32.82% |
Investing Cash Flow | 65.0M | ↑ 200.13% |
Financing Cash Flow | 235.0K | ↓ 99.63% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 52.0M | ↓ 227.15% |
Investing Cash Flow | -58.2M | ↓ 189.47% |
Financing Cash Flow | 10.1M | ↑ 4199.15% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -38.2M | ↓ 173.44% |
Investing Cash Flow | 82.9M | ↓ 242.61% |
Financing Cash Flow | 133.6M | ↑ 1222.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 100.4M | ↓ 362.79% |
Investing Cash Flow | 66.5M | ↓ 19.85% |
Financing Cash Flow | 16.0M | ↓ 87.99% |
Sell
Neutral
Buy
Exact Sciences Corporation is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Exact Sciences Corporation | -2.12% | -2.55% | -5.74% | -53.41% | -33.56% |
Idexx Laboratories, Inc. | -10.24% | 11.37% | -5.41% | -12.8% | 114.97% |
Agilent Technologies Inc. | -8.81% | 21.39% | -4.15% | -2.89% | 75.66% |
Thermo Fisher Scientific, Inc. | -4.39% | 17.97% | -4.51% | 11.61% | 107.78% |
Danaher Corp. | -4.73% | 15.42% | -7.18% | -6.88% | 84.76% |
Iqvia Holdings Inc. | -9.64% | 24.16% | 12.37% | 0.95% | 69.75% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Exact Sciences Corporation | NA | NA | -1.07 | -0.85 | -0.07 | -0.03 | NA | 17.34 |
Idexx Laboratories, Inc. | 47.4 | 47.4 | 4.75 | 11.13 | 0.81 | 0.23 | NA | 17.88 |
Agilent Technologies Inc. | 31.68 | 31.68 | 2.7 | 5.5 | 0.21 | 0.08 | 0.01 | 21.12 |
Thermo Fisher Scientific, Inc. | 35.1 | 35.1 | 2.81 | 21.55 | 0.13 | 0.05 | 0.0 | 120.87 |
Danaher Corp. | 41.83 | 41.83 | 3.13 | 7.62 | 0.08 | 0.04 | 0.0 | 72.36 |
Iqvia Holdings Inc. | 31.29 | 31.29 | 1.33 | 11.11 | 0.23 | 0.05 | NA | 33.67 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Exact Sciences Corporation | Buy | $11.1B | -33.56% | NA | -8.17% |
Idexx Laboratories, Inc. | Buy | $39.7B | 114.97% | 47.4 | 23.08% |
Agilent Technologies Inc. | Buy | $38.8B | 75.66% | 31.68 | 18.35% |
Thermo Fisher Scientific, Inc. | Buy | $206.7B | 107.78% | 35.1 | 13.99% |
Danaher Corp. | Buy | $175.0B | 84.76% | 41.83 | 19.94% |
Iqvia Holdings Inc. | Buy | $41.5B | 69.75% | 31.29 | 9.06% |
Vanguard Group Inc
JPMorgan Chase & Co
BlackRock Inc
Wellington Management Company LLP
Capital World Investors
ARK Investment Management LLC
Exact Sciences Corporation’s price-to-earnings ratio stands at None
Read Moreexact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com
Organization | Exact Sciences Corporation |
Employees | 6500 |
CEO | Mr. Kevin T. Conroy |
Industry | Health Technology |